Regenerative
Gene therapy for a fatal infant muscle disease showed no liver toxicity in animal studies
By Life and Health Today Staff, . Life and Health Today.
What the disease is and why the therapy matters
X-linked myotubular myopathy is a rare genetic condition caused by mutations in a gene called MTM1, which normally instructs the body to make a protein called myotubularin. Without it, muscles fail to develop properly. Boys born with the condition typically cannot breathe without a ventilator and have almost no muscle tone. Many die in early childhood.
The therapy under study, resamirigene bilparvovec, uses a modified virus called AAV8 (adeno-associated virus serotype 8) as a delivery vehicle to carry a working copy of the MTM1 gene into muscle cells. It is in clinical development, meaning it is not approved for general use.
What the human trial found, and what went wrong
In the first-in-human trial, called ASPIRO (registered as NCT03199469), resamirigene bilparvovec was associated with reduced dependence on ventilators and improvements in motor function in boys with the condition, according to the study published in Molecular Therapy. Those results were described as unprecedented.
But four of the 24 children who received the therapy died after developing cholestatic liver failure, a condition in which bile cannot flow properly from the liver, causing it to back up and damage liver cells. That outcome halted the trial's momentum and raised urgent questions about what the therapy was doing to the liver.
What the animal studies showed
Researchers went back to large-animal safety data collected before and alongside the human trial to look for clues. Healthy infant cynomolgus monkeys and juvenile dogs that had the canine equivalent of the disease received relatively high doses of the therapy or its canine version.
In both species, the viral vector carrying the gene accumulated most heavily in the liver, while the myotubularin protein it produced was expressed most strongly in heart or skeletal muscle, which is where the therapy was aimed. Despite the liver being the organ that absorbed the most vector, neither the monkeys nor the dogs showed elevated bilirubin (a marker of liver stress) or any other sign of liver toxicity, according to the Molecular Therapy report.
The authors describe the therapy as generally well-tolerated in both species at the doses tested.
What the animal data can and cannot tell us
The absence of liver toxicity in monkeys and dogs does not explain why four children in the human trial died of liver failure. Animal models, even large ones chosen for their biological similarity to humans, do not always predict what happens in people, and the children in ASPIRO were already severely ill, which may have affected how their livers responded.
What the animal data does establish is that the liver toxicity seen in the trial was not a straightforward, dose-dependent effect that would have been obvious in preclinical work. That distinction matters for researchers trying to understand whether the deaths reflected something specific to the human disease state, the children's individual biology, or something else entirely.
The study was retrospective, meaning the researchers looked back at existing animal data in light of what happened in the trial rather than designing the animal work to answer that question prospectively.
Where this leaves the therapy
Resamirigene bilparvovec remains in clinical development. The Molecular Therapy paper does not report on whether the human trial has resumed or under what conditions. For families affected by X-linked myotubular myopathy, the therapy's early efficacy signals remain meaningful, and the liver safety question remains open. Anyone considering enrollment in a gene therapy trial for this condition should discuss the full risk picture with a specialist who knows the current trial status.
Life & Health Today provides information for educational purposes only, not medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional.